Seeking Alpha
 

Theravance, Inc. (THRX)

- NASDAQ
  • Dec. 1, 2014, 9:05 AM
    • The Australian Pharmaceutical Benefits Scheme (PBS) approves the reimbursement of GlaxoSmithKline (NYSE:GSK) and Theravance's (NASDAQ:THRX) Anoro Ellipta (umeclidinium/vilantrol) for the maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Reimbursement will begin December 1, 2014.
    • COPD afflicts ~530K Australians.
    • Previously: Anoro Ellipta cleared in Australia
    | Comment!
  • Nov. 24, 2014, 8:02 AM
    • The European Commission approves AstraZeneca's (NYSE:AZN) Duaklir Genuair (aclidium bromide/formoterol fumarate 340/12 mcg) for the maintenance bronchodilator treatment in adults with chronic obstructive pulmonary disease (COPD).
    • The product is a fixed dose combination of two approved long-acting bronchodilators with different mechanisms of action. Aclidium bromide is an anticholinergic or long-acting muscarinic antagonist that produces bronchodilation by inhibiting the muscarinic M3 receptor in the airway smooth muscle. Formoterol fumarate is a long-acting beta-agonist that stimulates the B2-receptors in the bronchial smooth muscle resulting in bronchodilation. Both are currently approved as stand-alone therapies for the maintenance treatment of COPD in the U.S. and Europe.
    • Genuair is a multi-dose pre-loaded dry powder inhaler that utilizes optical and acoustic signals to inform the patient that the correct dose has been delivered.
    • COPD-related tickers: (NYSE:GSK) (NYSE:NVS) (NASDAQ:THRX) (NASDAQ:REGN) (NYSE:SNY) (NYSE:TEVA) (OTCQX:RHHBY)
    | Comment!
  • Nov. 19, 2014, 8:32 AM
    • GlaxoSmithKline (NYSE:GSK) has finished recruiting 2,800 people with Chronic Obstructive Pulmonary Disease (COPD) living in Salford, England to participate in a one-year Phase 3 open-label study to explore the effectiveness of Relvar Ellipta (fluticasone furoate "FF"/vilanterol "VI" 100/25 mcg) compared to other COPD treatments when used in a broad group of people living and managing their COPD on a daily basis.
    • The Salford Lung Study is the first "real-world" study of its kind in the world for a medicine prior to approval, conducted in one geographic location and run by GSK in collaboration with local healthcare providers.
    • Traditionally, drugs are evaluated in carefully-controlled randomized controlled trials on specific patient populations. Frequently, these trials exclude patients with additional conditions, or co-morbidities, that could influence the outcome. There is a need for additional information to complement the results from randomized trials in order to better understand a drug's potential when used in under real world circumstances. The Salford Lung Study is designed to provide this information.
    • The primary endpoint of the Salford trial is the mean annual rate of moderate and severe exacerbations. The study should finish in late 2015 with the first results expected in 2016.
    • Related ticker: (NASDAQ:THRX)
    | Comment!
  • Nov. 11, 2014, 7:44 AM
    • Dupilumab, a fully-human monoclonal antibody being co-developed by Sanofi (NYSE:SNY) (OTCQB:SNYNF) and Regeneron Pharmaceuticals (NASDAQ:REGN), showed showed positive results in a 776-patient Phase 2b dose-ranging clinical trial in adults with moderate-to-severe uncontrolled asthma.
    • The three highest doses of dupilumab in combination with standard-of-care therapy met the primary endpoint of a statistically significant improvement from baseline in forced expiratory volume over one second (FEV1) at week 12 in patients with high blood eosinophils (>= 300 cells/microliter) compared to placebo in combination with standard-of-care therapy. Also, two doses of dupilumab (200 mg every other week and 300 mg every other week) showed a statistically significant improvement in mean percent change in FEV1 and a reduction in severe exacerbations, both in the high eosinophils group and the overall study population.
    • Dupilumab blocks IL-4 and IL-13, two cytokines required by the Th2 immune response. Some researchers believed that targeting the Th2 pathway would limit the benefit in asthmatics with high eosinophils, but this study demonstrated that it could be effective. Final results from the trial will be presented at a future medical conference.
    • Sanofi plans to proceed to Phase 3 development.
    • Asthma-related tickers: (NYSE:GSK) (NYSE:TEVA) (NYSE:AZN) (OTCQX:RHHBY) (NASDAQ:AMGN) (NYSE:MRK) (NYSE:NVS) (NASDAQ:THRX)
    | 2 Comments
  • Nov. 3, 2014, 1:06 PM
    • The FDA accepts Boehringer Ingelheim's NDA for Spiriva Respimat (tiotropium bromide) for the maintenance treatment of asthma in patients at least 12 years old who remain symptomatic on at least inhaled corticosteroids.
    • Spiriva is currently cleared for the maintenance treatment of bronchospasm (HandiHaler) associated with chronic obstructive pulmonary disease (COPD) and to reduce COPD exacerbations.
    • The Respimat inhaler provides a pre-measured amount of medicine in a slow moving mist that helps the patient inhale the drug. It is designed to deliver the medication in a way that does not depend on how fast air is breathed in from the inhaler.
    • Asthma and COPD-related tickers: (THRX -3%)(GSK -0.3%)(AZN -0.8%)(NVS -1.3%)(REGN +0.6%)(SNY -1.5%)(TEVA +1.5%)(OTCQX:RHHBY -1.3%)
    | Comment!
  • Oct. 31, 2014, 2:03 PM
    • Theravance (THRX +1.6%) Q3 results: Revenues: $1M (+150.0%); Operating Expenses: $10.5M (+29.6%); Operating Loss: ($9.5M) (-23.4%); Net Loss: ($21.3M) (+54.7%); Loss Per Share: ($0.19) (+56.8%); Quick Assets: $310.9M (-40.3%).
    • No guidance given.
    | Comment!
  • Oct. 30, 2014, 6:49 PM
    | Comment!
  • Oct. 30, 2014, 4:26 PM
    • Theravance (NASDAQ:THRX): Q3 EPS of -$0.19 misses by $0.05.
    • Revenue of $1M (+150.0% Y/Y) misses by $5.27M.
    • Shares +0.19%.
    • Press Release
    | Comment!
  • Oct. 23, 2014, 7:04 PM
    • Theravance (THRX +1.1%) will report Q3 results on October 30 after the close. The conference call will begin at 2:00 pm PT/5:00 pm ET.
    • Consensus view is a loss of ($0.14) per share on revenues of $6.3M.
    | Comment!
  • Oct. 17, 2014, 9:58 AM
    • Theravance (THRX -1.8%) and collaboration partner GlaxoSmithKline's (GSK +1.7%) Anoro Ellipta (umeclidinium/vilanterol) improved lung function better in patients with chronic obstructive pulmonary disease (COPD) than Boehringer Ingelheim's Spiriva HandiHaler (tiotropium bromide).
    • In a randomized 905-patient 24-week multicenter study, Anoro Ellipta demonstrated a statistically significant improvement in lung function (p<0.001) compared to Spiriva as measured by trough-forced expiratory volume in one second (FEV1) at the end of the treatment period (day 169).
    • GSK SVP and Head, Global Respiratory Franchise Darrell Baker says, "We are pleased to announce the publication of these important data comparing Anoro Ellipta with tiotropium. These results support the lung function benefit of Anoro Ellipta in the treatment of appropriate patients with COPD. We hope the publication will inform physicians as they consider which treatment option is best to meet their individual patient's needs."
    | 2 Comments
  • Oct. 9, 2014, 4:49 PM
    • Theravance (THRX -5.1%) appoints Eric d'Esparbes as SVP and CFO. He joins the firm from Joule Unlimited where he had similar duties.
    | Comment!
  • Sep. 4, 2014, 9:42 AM
    • GlaxoSmithKline (GSK -0.5%) subsidiary GSK Japan launches bronchodilator treatment Anoro Ellipta (umeclidinium/vilanterol) triggering a $10M milestone payment from Theravance (THRX -0.2%) to Glaxo. The two companies entered into a collaboration agreement in 2002 to develop the product.
    | Comment!
  • Aug. 14, 2014, 2:14 PM
    | Comment!
  • Aug. 6, 2014, 7:38 PM
    | Comment!
  • Aug. 6, 2014, 5:18 PM
    • Theravance (THRX -1.5%) promotes SVP and CFO Michael W. Aquiar to President and CEO effective August 15, 2014. He replaces Rick E. Winningham who will remain Chairman of the Board and will transition to full-time CEO of Theravance Biopharma on August 15, 2014.
    | Comment!
  • Aug. 6, 2014, 5:02 PM
    • Theravance (THRX -1.5%) Q2 results: Revenues: $934K (-29.3%); Operating Expenses: $10.7M (+30.5%); Operating Loss: ($9.8M) (-42.0%); Net Loss: ($63.6M) (-74.7%); Loss Per Share: ($0.57) (-54.1%); Quick Assets: $368.8M (-29.1%).
    • No guidance given.
    | Comment!
THRX vs. ETF Alternatives
Company Description
Theravance Inc., is a biopharmaceutical company with a pipeline of internally discovered product candidates and collaborations with pharmaceutical companies.
Sector: Healthcare
Industry: Biotechnology
Country: United States